Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623996 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| SCHEMBL29387616 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| SCHEMBL14159217 | 0.91 | LMNA (0.60) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| SCHEMBL14572341 | 0.91 | LMNA (0.60) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| Sulfuric Acid SCHEMBL6515066 | 0.91 | TSHR (0.55) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| Sulfuric Acid SCHEMBL2532781 | 0.91 | TSHR (0.55) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| Phosphoric Acid SCHEMBL6538345 | 0.91 | TSHR (0.55) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| SCHEMBL5282524 | 0.87 | NPSR1 (0.55) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| SCHEMBL5282522 | 0.87 | NPSR1 (0.55) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 | |
| SCHEMBL4615823 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TSHRNPSR1MAPK1KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008066370-A1 | NEPHELIUM LAPPACEUM EXTRACTS FOR COSMECEUTICAL AND NUTRACEUTICAL APPLICATIONS | SIRIM BERHAD (MY) | 2008-06-05 | — | — | WO | claimed |
| EP-0445135-B1 | IMMOGENICALLY ACTIVE FRACTIONS OF BORRELIA BURGDORFERI | SYMBICOM AB (SE) | 1997-03-19 | — | — | EP | claimed |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260140117-A1 | Methods for Diagnosing and Treating Vestibular Schwannoma | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4743106-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | The Regents of University of California (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12631653-B2 | Methods for diagnosing and treating uveitis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-12558336-B2 | Metabolic rescue of retinal degeneration | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250347701-A1 | METHODS FOR MONITORING MOLECULAR BIOMARKERS FOR AGING AND DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-11-13 | — | — | US | disclosed |
| WO-2025230706-A1 | IMMUNE CHECKPOINT INHIBITORS FOR USE IN CARDIAC REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-06 | — | — | WO | disclosed |
| US-12459945-B2 | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents | Madera Therapeutics, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250093370-A1 | BIOMARKERS AND THEIR USE IN DIAGNOSING PARKINSON'S DISEASE, VITREORETINAL DISEASES, AND AGE-RELATED PATHOLOGIES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-03-20 | — | — | US | disclosed |
| US-5374530-A | Using synthetic antigen /NANP/20 | ENIRICERCHE S.P.A. (IT) | 1994-12-20 | — | — | US | disclosed |
| EP-0353822-B1 | IMMUNOENZYMATIC SINGLE-PLATE ELISA METHOD WITH COMPETITIVE INHIBITITION FOR DETECTING ANTISPOROZOITE ANTIBODIES OF PLASMODIUM FALCIPARUM | ENIRICERCHE S.p.A. (IT) | 1993-09-01 | — | — | EP | disclosed |
| EP-0535239-A1 | COLLAGEN ASSAYING METHOD AND KIT | SHISEIDO COMPANY LIMITED (JP) | 1993-04-07 | — | — | EP | disclosed |
| US-5059524-A | Binding and blocking the HLA-B7 antigen with a first antibody, then using an HLA-B27-specific labelled antibody; diagnosis for ankylosing spondylitis; rheumatic diseases | THE UNIVERSITY OF MELBOURNE (AU) | 1991-10-22 | — | — | US | disclosed |
| EP-0353822-A1 | Immunoenzymatic single-plate elisa method with competitive inhibitition for detecting antisporozoite antibodies of plasmodium falciparum | ENIRICERCHE S.p.A. (IT) | 1990-02-07 | — | — | EP | disclosed |
| EP-0258322-A1 | HLA-B27 TESTING | THE UNIVERSITY OF MELBOURNE (AU) | 1988-03-09 | — | — | EP | disclosed |
| WO-1987005398-A1 | HLA-B27 TESTING | THE UNIVERSITY OF MELBOURNE (AU) | 1987-09-11 | — | — | WO | disclosed |
| EP-0180486-A1 | Hybrid cells secreting antiidiotypic antibodies, monoclonal antibodies secreted by these hybrid cells, their preparation and their application | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1986-05-07 | — | — | EP | disclosed |
| WO-1986001222-A1 | NEW HYBRIDE CELLS SECRETING ANTI-IDIOTYPIC ANTIBODIES, NEW MONOCLONAL ANTIBODIES SECRETED BY SAID HYBRIDE CELLS, PREPARATION AND APPLICATION THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1986-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558336-B2 | Metabolic rescue of retinal degeneration | ALDH1A2, ARRB1, RBP1 | ALDH1A1 1137/4885TSHR 4221/4885NPSR1 2497/4885 |
| US-20260140117-A1 | Methods for Diagnosing and Treating Vestibular Schwannoma | MIF, CXCL10, CCL2 | ALDH1A1 4497/4885TSHR 797/4885NPSR1 2242/4885 |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | ALDH1A1 1889/4885TSHR 975/4885NPSR1 1374/4885 |
| US-12459945-B2 | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents | CLPP, PRCP, PREP | ALDH1A1 2284/4885TSHR 3820/4885NPSR1 3099/4885 |
| US-12631653-B2 | Methods for diagnosing and treating uveitis | LCP2, LGALS1, LGALS2 | ALDH1A1 4142/4885TSHR 2882/4885NPSR1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.